PRLog - July 23, 2014 - MACOMB, Mich. -- GraMedica® announces this week its first HyProCure® International Centers of Excellence (COE) facilities in Australia. The COE program of recognizing expert physicians, medical groups, and health care centers accomplished at performing HyProCure® Extra-Osseous TaloTarsal Stabilization (EOTTS) procedures and providing consummate post-operative care.
GraMedica's First ICOE in Australia
The first International Center of Excellence from Australia is acknowledged for their staff’s assurance to improving the quality of life of patients with foot and ankle disorders by using state-of-the-
A significant number of children and adults suffer lack of mobility and pain from excessive hindfoot motion, also known as congenital/acquired talotarsal joint dislocation and hyperpronation, a surgically correctable condition that results in the misalignment of the foot and other major structures of the body. The minimally invasive HyProCure® EOTTS procedure provides many patients with immediate and permanent correction for congenital/acquired talotarsal joint dislocation. Left untreated, congenital/acquired talotarsal joint dislocation can lead to serious, long-term foot, knee, hip, and back related issues that often require much more aggressive forms of surgery.
GraMedica® is the Macomb, Michigan developer and manufacturer of HyProCure®, a surgical stent that has been used in over 27,000 procedures worldwide to treat congenital/acquired talotarsal joint dislocation. HyProCure® International Center of Excellence is a program to reach out to a large patient population, designed to increase the awareness and medical services provided by experts in foot and ankle care.
Future announcements are expected regarding GraMedica’s HyProCure® International Centers of Excellence located in other parts of the world.
For more information Email: international@